Radiology Business April 4, 2024
A novel blood test could eliminate millions in spending on PET imaging to assess for Alzheimer’s disease, according to new research.
The approach analyzes levels of amyloid proteins using highly sensitive mass spectrometry. Experts believe the blood test could help physicians to determine whether the degenerative disease is the cause of mild cognitive impairment, eliminating the need for imaging.
Up to 99% of patients with a negative result for amyloid proteins, based on a PET scan, would likely be negative using the blood-based approach, researchers detailed in Frontiers in Neurology [1].
“The findings of this analysis in a large cohort have significant implications for AD care management because they potentially mean many patients could benefit from this type of blood-based...
Today's Sponsors
Today's Sponsor